EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

Przemysław R Kac, Katheryn A Q Cousins, Alicja Szadziewska, Leslie M Shaw, Michael Turton, Vivianna M Van Deerlin, Peter Harrison, Henrik Zetterberg, David A Wolk, Corey T McMillan, Douglas Galasko, Jörg Hanrieder und 4 weitere

Acta Neuropathologica · 24.06.2026 · 151 (1)

DOI: 10.1007/s00401-026-03042-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 24.06.2026. Verfasst von Przemysław R Kac und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 8…. Hauptthemen laut MEDLINE: tau Proteins, Frontotemporal Lobar Degeneration, Frontotemporal Dementia. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Alzheimer's Drug Discovery Foundation, HORIZON EUROPE European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Across tauopathies—Alzheimer’s disease (AD), frontotemporal lobar degeneration due to tau (FTLD-tau)—we compared cerebrospinal fluid (CSF) biomarkers of phosphorylated-tau (p-tau) p-tau181, p-tau212, tau368, total tau (t-tau), and the tau368/t-tau ratio, and tested differentiation from non-tau (FTLD-TDP, neuronal α-synuclein disease (αSyn), and controls). In AD, CSF p-tau181 and p-tau212 were significantly higher than in all other groups, including FTLD-tau, while tau368/t-tau was significantly lower. With the aim to combine tau phosphorylation biomarkers (p-tau181 and p-tau212) with biomarkers for severity of tau pathology (tau368), we made ratios between these biomarkers and examined their diagnostic accuracy in FTLD after excluding high/intermediate AD neuropathologic change (ADNC). CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved. Levels of the ratios were increased in behavioral and primary progressive aphasia variants of tauopathies when compared to FTLD-TDP. Furthermore, the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions. These results suggest unique patterns of increased relative levels of p-tau epitopes in CSF among ADNC and FTLD-tau could improve the diagnosis of tauopathies and inform inclusion criteria in clinical trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsFrontotemporal Lobar DegenerationFrontotemporal DementiaHumansBiomarkersMalePhosphorylationFemaleAgedMiddle AgedAlzheimer DiseaseTauopathiesalpha-SynucleinBrain

Stichwörter der Autor:innen

Alzheimer’s diseaseBiomarkersCerebrospinal fluidFrontotemporal lobar degenerationTau368p-Tau

Substanzen

tau ProteinsBiomarkersMAPT protein, humanalpha-Synuclein

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80, Mölndal, Sweden. przemyslaw.kac@gu.se.
  • Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA. przemyslaw.kac@gu.se.
  • Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80, Mölndal, Sweden.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Bioventix Plc, Farnham, GU9 7SX, UK.

Förderung

  • Vetenskapsrådet
  • Alzheimer's Drug Discovery Foundation
  • HORIZON EUROPE European Research Council
  • Hjärnfonden
  • Swedish State Support for Clinical Research
  • UK Dementia Research Institute
  • Alzheimer's Association
  • the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie

Zitieren

APA

Kac, P. R., Cousins, K. A. Q., Szadziewska, A., Shaw, L. M., Turton, M., Van Deerlin, V. M., Harrison, P., Zetterberg, H., Wolk, D. A., McMillan, C. T., Galasko, D., Hanrieder, J., Lee, E. B., Kvartsberg, H., Irwin, D. J., & Blennow, K. (2026). Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP. Acta Neuropathologica, 151(1). https://doi.org/10.1007/s00401-026-03042-1

Vancouver

Kac PR, Cousins KAQ, Szadziewska A, Shaw LM, Turton M, Van Deerlin VM, et al. Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP. Acta Neuropathologica. 2026;151(1). doi:10.1007/s00401-026-03042-1

BibTeX
@article{Kac2026,
  author = {Kac, Przemysław R and Cousins, Katheryn A Q and Szadziewska, Alicja and Shaw, Leslie M and Turton, Michael and Van Deerlin, Vivianna M and Harrison, Peter and Zetterberg, Henrik and Wolk, David A and McMillan, Corey T and Galasko, Douglas and Hanrieder, Jörg and Lee, Edward B and Kvartsberg, Hlin and Irwin, David J and Blennow, Kaj},
  title = {Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP},
  journal = {Acta Neuropathologica},
  year = {2026},
  volume = {151},
  number = {1},
  doi = {10.1007/s00401-026-03042-1}
}
Kostenlos starten →